Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.

Abstract

Combination chemotherapy holds promise for improving outcomes in malignancy when compared with single-agent approaches. Care must be taken to avoid overlapping toxicity and to utilize agents with differing mechanisms of action. A phase I dose-finding trial was performed to determine the maximally tolerated dose (MTD) of a concurrent toceranib and… (More)
DOI: 10.1111/vco.12232

Topics

4 Figures and Tables

Cite this paper

@article{Pellin2017SafetyEO, title={Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.}, author={Mackenzie Pellin and R M Wouda and K. Robinson and K Tsimbas and Ilene D. Kurzman and Barbara J Biller and D. M. Vail}, journal={Veterinary and comparative oncology}, year={2017}, volume={15 3}, pages={919-931} }